Advertisement

EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy

Published:March 06, 2020DOI:https://doi.org/10.1016/j.cllc.2019.11.017

      Abstract

      Background

      Second-line immunotherapy (IO) has shown an overall survival benefit. However, only 18% to 20% of patients with advanced non–small-cell lung cancer (aNSCLC) will respond, with a median progression-free survival (PFS) of 2 to 4 months. Thus, biomarkers to select those patients most likely to benefit from IO are greatly needed.

      Patients and Methods

      We conducted a retrospective analysis of 154 patients with aNSCLC who had received anti–programmed cell death 1 therapy as second line or further treatment. We assessed the absolute neutrophil, lymphocyte, monocyte, and eosinophil counts at baseline (T0) and the second (T1) and third (T2) cycles. The neutrophil/lymphocyte ratio (NLR), derived-NLR (dNLR), lymphocyte/monocyte ratio (LMR), and their percentage of change at T1 and T2 compared with T0 were evaluated. The clinical characteristics and lactate dehydrogenase (LDH) level were also considered. Univariate and multivariate analyses were performed. Significant biomarkers for PFS on multivariate analysis were combined in a prognostic score.

      Results

      For overall survival, the negative prognostic biomarkers were Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, NLR at T0, and dNLR at T1; the LMR at T0, T1, and T2 was identified as a positive prognostic biomarker. For PFS, the negative prognostic biomarkers were ECOG PS 2, liver metastases, NLR at T0, dNLR at T1 and T2, and ≥ 30% increase of NLR from T0 to T1; the positive prognostic biomarkers were heavy smoking, LDH, and LMR at T2. The ≥ 30% increase of LMR from T0 to T1 and T0 to T2 correlated with the overall response rate. A prognostic score (EPSILoN score; smoking, ECOG PS, liver metastases, LDH, NLR) identified 3 prognostic groups (median PFS, 10.2, 4.9, and 1.7 months, respectively; P < .001).

      Conclusions

      The EPSILoN score combines 5 baseline clinical and blood biomarkers and can help to identify patients with aNSCLC who will most likely benefit from second-line IO. Further studies are warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Horn L.
        • Spigel D.R.
        • Vokes E.E.
        • et al.
        Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057).
        J Clin Oncol. 2017; 35: 3924-3933
        • Reck M.
        • Rodríguez-Abreu D.
        • Robinson A.G.
        • et al.
        Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.
        N Engl J Med. 2016; 375: 1823-1833
        • Herbst R.S.
        • Baas P.
        • Kim D.W.
        • et al.
        Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
        Lancet. 2016; 387: 1540-1550
        • Rittmeyer A.
        • Barlesi F.
        • Waterkamp D.
        • et al.
        Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
        Lancet. 2017; 389: 255-265
        • Planchard D.
        • Popat S.T.
        • Kerr K.
        • et al.
        Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2018; 29: iv192-iv237
        • Rebuzzi S.E.
        • Bregni G.
        • Grassi M.
        • et al.
        Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
        Immunotherapy. 2018; 10: 1123-1132
        • Kiriu T.
        • Yamamoto M.
        • Nagano T.
        • et al.
        The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
        PLoS One. 2018; 13: e0193018
        • Russo A.
        • Franchina T.
        • Ricciardi G.R.R.
        • et al.
        Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non-small cell lung cancer (NSCLC) treated with nivolumab or docetaxel.
        J Cell Physiol. 2018; 233: 6337-6343
        • Park W.
        • Kwon D.
        • Saravia D.
        • et al.
        Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab.
        Clin Lung Cancer. 2018; 19: 280-288
        • Prelaj A.
        • Tay R.
        • Ferrara R.
        • Chaput N.
        • Besse B.
        • Califano R.
        Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
        Eur J Cancer. 2019; 106: 144-159
        • Diem S.
        • Schmid S.
        • Krapf M.
        • et al.
        Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
        Lung Cancer. 2017; 111: 176-181
        • Templeton A.J.
        • Ace O.
        • McNamara M.G.
        • et al.
        Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis.
        Cancer Epidemiol Biomarkers Prev. 2014; 23: 1204-1212
        • Shiroyama T.
        • Suzuki H.
        • Tamiya M.
        • et al.
        Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non–small cell lung cancer.
        Cancer Med. 2018; 7: 13-20
        • Ferrucci P.F.
        • Ascierto P.A.
        • Pigozzo J.
        • et al.
        Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
        Ann Oncol. 2016; 27: 732-738
        • Nakamura Y.
        • Kitano S.
        • Takahashi A.
        • et al.
        Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
        Oncotarget. 2016; 7: 77404-77415
        • Weide B.
        • Martens A.
        • Hassel J.C.
        • et al.
        Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab.
        Clin Cancer Res. 2016; 22: 5487-5496
        • Bagley S.J.
        • Kothari S.
        • Aggarwal C.
        • et al.
        Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
        Lung Cancer. 2017; 106: 1-7
        • Mezquita L.
        • Auclin E.
        • Ferrara R.
        • et al.
        Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
        JAMA Oncol. 2018; 4: 351-357
        • Nakaya A.
        • Kurata T.
        • Yoshioka H.
        • et al.
        Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
        Int J Clin Oncol. 2018; 23: 634-640
        • Garde-Noguera J.
        • Martin-Martorell P.
        • De Julián M.
        • et al.
        Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
        Clin Transl Oncol. 2018; 20: 1072-1079
        • Suh K.J.
        • Kim S.H.
        • Kim Y.J.
        • et al.
        Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
        Cancer Immunol Immunother. 2018; 67: 459-470
        • Tanizaki J.
        • Haratani K.
        • Hayashi H.
        • et al.
        Peripheral blood biomarkers associated with clinical outcome in non–small cell lung cancer patients treated with nivolumab.
        J Thorac Oncol. 2018; 13: 97-105
        • Contal C.
        • O’Quigley J.
        An application of changepoint methods in studying the effect of age on survival in breast cancer.
        Comput Stat Data Analysis. 1999; 30: 253-270
        • R Core Team
        R: a language and environment for statistical computing.
        R Foundation for Statistical Computing, Vienna, Austria2018
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Putzu C.
        • Cortinovis D.L.
        • Colonese F.
        • et al.
        Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with nivolumab.
        Cancer Immunol Immunother. 2018; 67: 1349-1353
        • Tamiya M.
        • Tamiya A.
        • Inoue T.
        • et al.
        Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial.
        PLoS One. 2018; 13: e0192227
        • Lin S.Y.
        • Yang C.Y.
        • Liao B.C.
        • et al.
        Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: real-world data in Taiwan.
        J Cancer. 2018; 9: 1813-1820
        • Middleton G.
        • Brock K.
        • Summers Y.
        • et al.
        Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trial.
        Ann Oncol. 2018; 29: viii493-viii547
        • Pirker R.
        Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?.
        ESMO Open. 2018; 3: e000421
        • Schmid S.
        • Diem S.
        • Li Q.
        • et al.
        Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).
        Cancer Immunol Immunother. 2018; 67: 1825-1832
        • O’Kane G.M.
        • Leighl N.B.
        Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC? Current evidence and future perspectives.
        Transl Lung Cancer Res. 2016; 5: 628-636
        • Tumeh P.C.
        • Hellmann M.D.
        • Hamid O.
        • et al.
        Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC.
        Cancer Immunol Res. 2017; 5: 417-424
        • Balatoni T.
        • Ladányi A.
        • Fröhlich G.
        • et al.
        Biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab.
        ([e-pub ahead of print]. Pathol Oncol Res)
        https://doi.org/10.1007/s12253-018-0466-9
        (accessed September 17, 2018)
        • Capone M.
        • Giannarelli D.
        • Mallardo D.
        • et al.
        Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
        J Immunother Cancer. 2018; 6: 74
        • Rosner S.
        • Kwong E.
        • Shoushtari A.N.
        • et al.
        Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
        Cancer Med. 2018; 7: 690-697
        • Martens A.
        • Wistuba-Hamprecht K.
        • Geukes Foppen M.
        • et al.
        Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab.
        Clin Cancer Res. 2016; 22: 2908-2918
        • Lalani A.A.
        • Xie W.
        • Martini D.J.
        • et al.
        Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
        J Immunother Cancer. 2018; 6: 5
        • Bilen M.A.
        • Dutcher G.M.A.
        • Liu Y.
        • et al.
        Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab.
        Clin Genitourin Cancer. 2018; 16: e563-e575
        • Soyano A.E.
        • Dholaria B.
        • Marin-Acevedo J.A.
        • et al.
        Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies.
        J Immunother Cancer. 2018; 6: 129
        • Parikh K.
        • Kumar A.
        • Ahmed J.
        • et al.
        Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer.
        Cancer Immunol Immunother. 2018; 67: 1365-1370
        • Khunger M.
        • Patil P.D.
        • Khunger A.
        • et al.
        Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
        PLoS One. 2018; 13: e0197743
        • Zer A.
        • Sung M.R.
        • Walia P.
        • et al.
        Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer.
        Clin Lung Cancer. 2018; 19: 426-434
        • Sacdalan D.B.
        • Lucero J.A.
        • Sacdalan D.L.
        Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
        Onco Targets Ther. 2018; 11: 955-965
        • Jiang T.
        • Qiao M.
        • Zhao C.
        • et al.
        Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis.
        Cancer Immunol Immunother. 2018; 67: 713-727
        • Cao D.
        • Xu H.
        • Xu X.
        • Guo T.
        • Ge W.
        A reliable and feasible way to predict the benefits of nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies.
        Oncoimmunology. 2018; 7: e1507262
        • Fukui T.
        • Okuma Y.
        • Nakahara Y.
        • et al.
        Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study.
        Clin Lung Cancer. 2019; 20: 208-214.e2
        • Proctor M.J.
        • McMillan D.C.
        • Morrison D.S.
        • Fletcher C.D.
        • Horgan P.G.
        • Clarke S.J.
        A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.
        Br J Cancer. 2012; 107: 695-699
        • Tay R.
        • Prelaj A.
        • Califano R.
        Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.
        J Thorac Dis. 2018; 10: S1494-S1502
        • Prelaj A.
        • Lo Russo G.
        • Signorelli D.
        • et al.
        EPSILoN score: validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy.
        Ann Oncol. 2019; 30: ii38-ii68
        • Rebuzzi S.E.
        • Leonetti L.
        • Tiseo M.
        • Facchinetti F.
        Advances in the prediction of long-term effectiveness of immune checkpoint blockers for NSCLC.
        Immunotherapy. 2019; 11: 993-1003
        • Hoang T.
        • Xu R.
        • Schiller J.H.
        • Bonomi P.
        • Johnson D.H.
        Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data.
        J Clin Oncol. 2005; 23: 175-183
        • Hoang T.
        • Dahlberg S.E.
        • Sandler A.B.
        • Brahmer J.R.
        • Schiller J.H.
        • Johnson D.H.
        Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
        J Thorac Oncol. 2012; 7: 1361-1368
        • Koch A.
        • Fohlin H.
        • Sörenson S.
        Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
        J Thorac Oncol. 2009; 4: 326-332
        • Guo D.
        • Li M.
        • Chen D.
        • et al.
        Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
        Future Oncol. 2019; 15: 625-635